MetaCap

Achieve Life Sciences (QUIT) vs Trinity Biotech (TRIB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Achieve Life Sciences is the larger company by market cap ($573.2 million vs $5.1 million), about 113.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QUIT-23.20%TRIB-7.56%
+24%-1%-25%
Oct 7, 20261 yearNov 20, 2026
QUIT-24.97%TRIB-8.97%
+19%-4%-27%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QUIT versus TRIB key metrics
MetricQUITTRIB
Share price$5.56$6.24
Market cap$573.25M$5.07M
1-day change-5.28%+13.76%
EPS (TTM)$-1.71$-60.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$61.55M
Revenue growth (YoY)—+8.31%
Net income (latest FY)$-54.65M$-31.79M
Gross margin—34.83%
Operating margin—-34.38%
Net margin—-51.64%
52-week high$8.64$52.50
52-week low$2.62$4.54
Distance from 52-week high-35.65%-88.11%
Analyst consensusstrong_buy—
Avg. price target upside+162.23%—
Average volume1.38M13.54K
Shares outstanding103.10M813.13K
Employees28287
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Achieve Life Sciences is about 113.0 times larger than Trinity Biotech by market value ($573.25M vs $5.07M).

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

About Trinity Biotech

TRIB stock →

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees

QUIT vs TRIB FAQ

Which is bigger, Achieve Life Sciences or Trinity Biotech?

Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $5.07M for Trinity Biotech (TRIB).

Are Achieve Life Sciences and Trinity Biotech in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons